Tranexamic acid reduces mortality in TBI patients with high brain voxel percentages

This study is a post hoc analysis of a randomized controlled trial (RCT) involving 550 patients diagnosed with moderate or severe traumatic brain injury (TBI). The study was conducted in both prehospital and in-hospital settings to evaluate the impact of tranexamic acid (TXA) on patient outcomes. Because this is a post hoc analysis, the results should be interpreted with caution as they were not the primary endpoints of the original trial design.

The intervention group received tranexamic acid (TXA), while the comparator group received a placebo. The specific dosing and administration protocols for TXA were not detailed in the provided data. The study focused on identifying whether specific imaging biomarkers could predict which patients would derive the most significant benefit from TXA therapy in the acute setting.

The primary outcome of interest was the interaction between TXA use, in-hospital survival, and the percentage of brain voxels within the 10-20 HU range. The analysis revealed a positive association between higher voxel percentages and improved outcomes following TXA administration (p = .04). This suggests that specific tissue characteristics on CT imaging may correlate with treatment efficacy.

In a specific subgroup analysis, patients with at least 3% voxels in the 10-20 HU range were evaluated. In this subgroup, TXA was associated with a relative risk of mortality of 0.41 compared with placebo (95% CI, 0.17-0.99; p = .04). This indicates a substantial reduction in mortality for patients meeting this specific imaging threshold when treated with tranexamic acid.

Safety and tolerability data were not reported in the provided results. Specific rates of adverse events, serious adverse events, or treatment discontinuations were not documented. Consequently, the safety profile of TXA specifically within this TBI cohort and in relation to the identified biomarker cannot be determined from this data set alone.

These findings provide a potential mechanism for identifying candidates who may benefit most from early TXA administration in TBI. However, because these results are derived from a post hoc analysis rather than a prospective trial designed to test this specific biomarker, they do not yet establish a definitive clinical standard. The 3% threshold is currently characterized as a promising biomarker but lacks the weight of a primary trial result.

Several limitations exist, most notably the fact that this is a post-hoc analysis. Such analyses are prone to type I errors and may not reflect findings from a prospective study. Furthermore, the lack of reported safety data limits the ability to assess the risk-benefit profile for clinicians. Prospective validation is required to confirm these findings before integrating this biomarker into clinical decision-making.

Clinically, the results suggest that a voxel percentage of at least 3% within the 10-20 HU CT density range may serve as a useful indicator for TXA efficacy in prehospital and in-hospital TBI management. However, clinicians should not rely on this biomarker alone for treatment decisions at this time. Questions remain regarding the specific physiological meaning of the 10-20 HU range and how quickly these measurements can be obtained in emergency settings to guide immediate TXA administration.